Pembrolizumab Treatment Study for Adults With Ultra-Rare Sarcomas A Phase 2 Trial Evaluating Immune Response and Side Effects

What this Trial Is About

Researchers are evaluating pembrolizumab as a treatment option for people with ultra-rare sarcomas, a group of uncommon cancers. The study aims to find out if pembrolizumab is effective and causes only mild or few side effects. It also investigates how the immune system responds to this drug, which works by blocking a protein called PD-1 to help the immune system target cancer cells. Participants will receive pembrolizumab through an intravenous infusion every 6 weeks, up to 8 doses. The study includes different sarcoma types such as pleomorphic liposarcoma, PEComa, epithelioid sarcoma, CIC-rearranged sarcoma, and sclerosing epithelioid fibrosarcoma. Treatment will continue for about 48 weeks or fewer based on dosing schedule. During the study, participants will be monitored for treatment response at 12 weeks and assessed for side effects over 2 years. Researchers will collect medical information and tumor details, and participants will undergo regular evaluations to track health status and immune response. The total participation may last up to 2 years with ongoing safety assessments.

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas